Comparing Two Methods to Follow Patients with Pancreatic Cysts

Active:	Yes
Cancer Type:	Unknown Primary	NCT ID:	NCT04239573
Trial Phases:		Protocol IDs:	EA2185 (primary) EA2185 ECOG-ACRIN-EA2185 NCI-2019-04790
Eligibility:	50 - 75 Years, Male and Female	Study Type:	Supportive care
Study Sponsor:	ECOG-ACRIN Cancer Research Group
NCI Full Details:	http://clinicaltrials.gov/show/NCT04239573

Summary

The purpose of this study is to compare the two approaches for monitoring pancreatic cysts. The study doctors want to compare more frequent monitoring vs less frequent monitoring in order to learn which monitoring method leads to better outcome for patients with pancreatic cysts.

Objectives

PRIMARY OBJECTIVE:
I. To compare the rates of unfavorable clinical outcomes in the two arms.

SECONDARY OBJECTIVES:
I. To compare rates of major surgical morbidity and/or mortality between arms.
II. To compare pancreatic cancer incidence and all-cause mortality across arms.
III. Compare institutional (direct) costs.
IV. Compare healthcare utilization of imaging, invasive testing, surgical, and other procedures across the two surveillance arms.
V. Compare patient (out-of-pocket and other indirect) costs.
VI. Describe diagnostic test and treatment pathways by arm.
VII. Compare patient reports of quality of life (QOL), situational anxiety.
VIII. Compare patient report of financial distress.
IX. Compare rates of non-adherence by arm assignment.
X. To evaluate and compare the predictive performance of known and future biomarkers for dysplasia or cancer.

EXPLORATORY OBJECTIVE:
I. To evaluate and compare the predictive accuracy of known and future radiomic markers for dysplasia and pancreatic cancer.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A (LOW INTENSITY SURVEILLANCE): Patients undergo magnetic resonance imaging (MRI), computed tomography (CT), or endoscopic ultrasound (EUS) at the beginning of the trial and MRI or CT again in 1 year. Following the first year, patients with no abnormalities repeat MRI or CT every 2 years. Patients with positive imaging features on MRI and CT at 1 or 2 years and with negative EUS, repeat MRI or CT in 1 year. Patients with negative imaging repeat MRI or CT in 2 years.

ARM B (HIGH INTENSITY SURVEILLANCE): Patients undergo MRI, CT, or EUS at the beginning of the trial. Patients with >= 1 and < 2 cm cyst undergo MRI or CT every 6 months for 1 year, then every 12 months for 2 years, and then every 24 months thereafter. Patients with >= 2 and < 3 cm cyst undergo EUS within 6 months, and if EUS is negative, patients repeat MRI or CT in 1 year. If second EUS is negative, patients undergo alternate MRI or CT and EUS every 12 months. Patients with cyst >= 3 cm undergo undergo alternate MRI or CT with EUS every 3-6 months.

All patients may also optionally undergo blood sample collection, biopsy and/or EUS-fine needle aspiration (FNA) on study.

After completion of imaging procedures, patients are followed up for 5 years from the date of registration.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.